Too Short or Unnecessarily Long: Walking the Fine Line

Overview

Journal Blood Adv

Specialty Hematology

Date 2024 Oct 15

PMID 39405073

Authors

Chiranjeevi Sainatham

Tania Jain

Affiliations

Soon will be listed here.

References

Logue J, Zucchetti E, Bachmeier C, Krivenko G, Larson V, Ninh D . Immune reconstitution and associated infections following axicabtagene ciloleucel in relapsed or refractory large B-cell lymphoma. Haematologica. 2020; 106(4):978-986. PMC: 8017820. DOI: 10.3324/haematol.2019.238634. View

Jain T, Sauter C, Shah G, Maloy M, Chan J, Scordo M . Safety and feasibility of chimeric antigen receptor T cell therapy after allogeneic hematopoietic cell transplantation in relapsed/ refractory B cell non-Hodgkin lymphoma. Leukemia. 2019; 33(10):2540-2544. PMC: 8224498. DOI: 10.1038/s41375-019-0476-y. View

Rejeski K, Subklewe M, Aljurf M, Bachy E, Balduzzi A, Barba P . Immune effector cell-associated hematotoxicity: EHA/EBMT consensus grading and best practice recommendations. Blood. 2023; 142(10):865-877. DOI: 10.1182/blood.2023020578. View

Jain T, Bar M, Kansagra A, Chong E, Hashmi S, Neelapu S . Use of Chimeric Antigen Receptor T Cell Therapy in Clinical Practice for Relapsed/Refractory Aggressive B Cell Non-Hodgkin Lymphoma: An Expert Panel Opinion from the American Society for Transplantation and Cellular Therapy. Biol Blood Marrow Transplant. 2019; 25(12):2305-2321. DOI: 10.1016/j.bbmt.2019.08.015. View

Jain T, Olson T, Locke F . How I treat cytopenias after CAR T-cell therapy. Blood. 2023; 141(20):2460-2469. PMC: 10646792. DOI: 10.1182/blood.2022017415. View

Maus M, Alexander S, Bishop M, Brudno J, Callahan C, Davila M . Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune effector cell-related adverse events. J Immunother Cancer. 2020; 8(2). PMC: 7745688. DOI: 10.1136/jitc-2020-001511. View

Oluwole O, Dholaria B, Knight T, Jain T, Locke F, Ramsdell L . Chimeric Antigen Receptor T-Cell Therapy in the Outpatient Setting: An Expert Panel Opinion from the American Society for Transplantation and Cellular Therapy. Transplant Cell Ther. 2023; 30(2):131-142. DOI: 10.1016/j.jtct.2023.11.008. View

Ly A, Sanber K, Tsai H, Ondo A, Mooney K, Shedeck A . Outpatient CD19-directed CAR T-cell therapy is feasible in patients of all ages. Br J Haematol. 2023; 203(4):688-692. DOI: 10.1111/bjh.19090. View

Hines M, Knight T, McNerney K, Leick M, Jain T, Ahmed S . Immune Effector Cell-Associated Hemophagocytic Lymphohistiocytosis-Like Syndrome. Transplant Cell Ther. 2023; 29(7):438.e1-438.e16. PMC: 10330221. DOI: 10.1016/j.jtct.2023.03.006. View

10.

Fusaroli M, Isgro V, Cutroneo P, Ferrajolo C, Cirillo V, Del Bufalo F . Post-Marketing Surveillance of CAR-T-Cell Therapies: Analysis of the FDA Adverse Event Reporting System (FAERS) Database. Drug Saf. 2022; 45(8):891-908. PMC: 9360149. DOI: 10.1007/s40264-022-01194-z. View

11.

Wesson W, Dima D, Suleman N, Saif M, Tabak C, Logan E . Timing of Toxicities and Non-Relapse Mortality Following CAR T Therapy in Myeloma. Transplant Cell Ther. 2024; 30(9):876-884. DOI: 10.1016/j.jtct.2024.06.012. View

12.

Ahmed N, Wesson W, Lutfi F, Porter D, Bachanova V, Nastoupil L . Optimizing the post-CAR T monitoring period in recipients of axicabtagene ciloleucel, tisagenlecleucel, and lisocabtagene maraleucel. Blood Adv. 2024; 8(20):5346-5354. PMC: 11568755. DOI: 10.1182/bloodadvances.2023012549. View

13.

Jain T, Knezevic A, Pennisi M, Chen Y, Ruiz J, Purdon T . Hematopoietic recovery in patients receiving chimeric antigen receptor T-cell therapy for hematologic malignancies. Blood Adv. 2020; 4(15):3776-3787. PMC: 7422135. DOI: 10.1182/bloodadvances.2020002509. View

14.

Elsallab M, Ellithi M, Lunning M, DAngelo C, Ma J, Perales M . Second primary malignancies after commercial CAR T-cell therapy: analysis of the FDA Adverse Events Reporting System. Blood. 2024; 143(20):2099-2105. DOI: 10.1182/blood.2024024166. View